Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pediatrics
Volume 2013 (2013), Article ID 703925, 4 pages
http://dx.doi.org/10.1155/2013/703925
Case Report

Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus

1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USA
2The Endocrine Group, LLP, Albany, NY 12206, USA

Received 5 April 2013; Accepted 28 July 2013

Academic Editors: A. T. Soliman and A. Spalice

Copyright © 2013 Sara J. Micale et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Diabetes Association, “Standards of medical care in diabetes,” Diabetes Care, vol. 35, supplement 1, pp. S11–S63, 2012. View at Google Scholar
  2. Today Study Group, “A clinical trial to maintain glycemic control in youth with type 2 diabetes,” The New England Journal of Medicine, vol. 366, pp. 2247–2256, 2012. View at Google Scholar
  3. S. Caprio, “Development of type 2 diabetes mellitus in the obese adolescent: a growing challenge,” Endocrine Practice, vol. 18, pp. 791–794, 2012. View at Google Scholar
  4. D. Dabelea, R. A. Bell, R. B. D'Agostino Jr. et al., “Incidence of diabetes in youth in the United States,” Journal of the American Medical Association, vol. 297, no. 24, pp. 2716–2724, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Kahn, “Type 2 diabetes in children and adolescents,” Diabetes Care, vol. 23, no. 3, pp. 381–389, 2000. View at Google Scholar · View at Scopus
  6. Victoza [package insert]. Princeton, NJ, USA: Novo Nordisk, 2012.
  7. J. B. Buse, M. Nauck, T. Forst et al., “Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (Duration-6): a randomized, open-label study,” The Lancet, vol. 381, no. 9861, pp. 117–124, 2013. View at Publisher · View at Google Scholar
  8. D. Klein, T. Battelino, D. J. Chatterjee et al., “Liraglutide trial in pediatric type 2 diabetes: safety, tolerability and pharmacokinetics/pharmacodynamics [poster],” Presented at the American Diabetes Association, Philadelphia, Pa, USA. Poster LB-59, 2012.
  9. K. L. Jones, S. Arslanian, V. A. Peterokova, J.-S. Park, and M. J. Tomlinson, “Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial,” Diabetes Care, vol. 25, no. 1, pp. 89–94, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. E. H. Livingston and J. W. Zylke, “Progress in obesity research: reason for optimism,” Journal of the American Medical Association, vol. 308, no. 11, pp. 1162–1164, 2012. View at Google Scholar
  11. C. L. Ogden, M. D. Carroll, B. K. Kit, and K. M. Flegal, “Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010,” Journal of the American Medical Association, vol. 307, no. 5, pp. 483–490, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. P. Kane, A. Abu-Baker, and R. S. Busch, “The utility of oral diabetes medications in type 2 diabetes of the young,” Current Diabetes Reviews, vol. 1, no. 1, pp. 83–92, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Steinbrook, “Testing medications in children,” The New England Journal of Medicine, vol. 347, no. 18, pp. 1462–1470, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act: Frequently Asked Questions on Pediatric Exclusivity (505A), The Pediatric, “Rule,” and their Interaction, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm077915.htm.